Obeticholic acid improved triptolide/lipopolysaccharide-induced hepatotoxicity by inhibiting caspase-11-GSDMD

Peishi Liang1,2, Shaoyun Zhou1, Ziqiao Yuan3

  • 1New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, China.

Insights

Triptolide and lipopolysaccharide cause liver injury by disrupting bile acid metabolism and activating pyroptosis. Obeticholic acid protects against this liver damage by targeting the farnesoid X receptor (FXR) pathway.

Area of Science:

  • Hepatology
  • Pharmacology
  • Molecular Biology

Background:

  • Drug-induced liver injury (DILI) is a significant clinical concern.
  • Triptolide (TP) and lipopolysaccharide (LPS) induce hepatotoxicity, involving complex mechanisms.
  • Abnormal bile acid metabolism and pyroptosis are implicated in liver pathogenesis.

Purpose of the Study:

  • Investigate the role of farnesoid X receptor (FXR) in TP/LPS-induced hepatotoxicity.
  • Explore the protective effects of obeticholic acid (OCA) in this model.
  • Elucidate the involvement of bile acid metabolism and pyroptosis.

Main Methods:

  • In vivo studies using C57BL/6 mice treated with OCA, TP, and LPS.
  • In vitro studies using AML12 cells treated with TP and TNF-α.
  • Intervention with FXR agonists (GW4064) and bile acid sequestrants (cholestyramine).

Main Results:

  • TP/LPS administration led to elevated serum total bile acid (TBA) levels due to FXR suppression.
  • FXR agonists and cholestyramine protected against TP/TNF-α-induced NLRP3 inflammasome and pyroptosis.
  • OCA pre-treatment attenuated liver injury by reducing serum TBA and inhibiting the caspase-11-GSDMD pyroptosis pathway.

Conclusions:

  • TP exacerbates LPS-induced liver injury by inhibiting the FXR-SHP axis, promoting pyroptosis.
  • OCA alleviates TP/LPS-induced hepatotoxicity via FXR activation, reducing TBA and pyroptosis.
  • FXR is a potential therapeutic target for managing drug-induced liver injury.